Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 2
1995 7
1996 5
1997 25
1998 26
1999 22
2000 19
2001 20
2002 18
2003 22
2004 11
2005 16
2006 14
2007 20
2008 16
2009 20
2010 18
2011 11
2012 6
2013 17
2014 13
2015 28
2016 23
2017 18
2018 20
2019 12
2020 18
2021 8
2022 4
2023 5
2024 5
2025 11
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

437 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin.
Meza LA, Green MD, Hackett JR, Neumann TA, Holmes FA. Meza LA, et al. Pharmacotherapy. 2003 Nov;23(11):1424-31. doi: 10.1592/phco.23.14.1424.31948. Pharmacotherapy. 2003. PMID: 14620389 Clinical Trial.
Additional objectives were to study the average number of filgrastim injections/cycle required to achieve ANC recovery and differences in outcome by cycle. ...Fifty percent of patients had ANC recovery to 10 x 10(3)/mm3 or greater by day 11 of the cycle, and 90% by day 13, …
Additional objectives were to study the average number of filgrastim injections/cycle required to achieve ANC recovery and difference …
Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis.
Cao S, Tao Q, Wang J, Zhang Q, Dong Y. Cao S, et al. Medicine (Baltimore). 2023 Nov 3;102(44):e34949. doi: 10.1097/MD.0000000000034949. Medicine (Baltimore). 2023. PMID: 37933074 Free PMC article.
BACKGROUND: To ascertain the efficacy and safety of cladribine, cytarabine, and filgrastim-based regimen in relapsed or refractory (R/R) AML patients. METHODS: Clinical studies were searched in PubMed, Cochrane Library, Embase data. ...
BACKGROUND: To ascertain the efficacy and safety of cladribine, cytarabine, and filgrastim-based regimen in relapsed or refractory (R …
Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Pettengell R, Bias P, Mueller U, Lang N. Pettengell R, et al. Support Care Cancer. 2016 Jun;24(6):2677-84. doi: 10.1007/s00520-015-3057-2. Epub 2016 Jan 16. Support Care Cancer. 2016. PMID: 26780505
This article presents pooled clinical data for tbo-filgrastim compared with Neupogen( ) (Amgen, Thousand Oaks, CA, USA) as well as tbo-filgrastim post-marketing safety data. ...The post-marketing safety profile of tbo-filgrastim was consistent with that obser …
This article presents pooled clinical data for tbo-filgrastim compared with Neupogen( ) (Amgen, Thousand Oaks, CA, USA) as well as tb …
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Huang H, Cella D, Zaino R, Fleming GF. Miller DS, et al. J Clin Oncol. 2020 Nov 20;38(33):3841-3850. doi: 10.1200/JCO.20.01076. Epub 2020 Sep 29. J Clin Oncol. 2020. PMID: 33078978 Free PMC article. Clinical Trial.
A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH. Dale DC, et al. Support Care Cancer. 2018 Jan;26(1):7-20. doi: 10.1007/s00520-017-3854-x. Epub 2017 Sep 22. Support Care Cancer. 2018. PMID: 28939926 Free PMC article.
PURPOSE: Filgrastim (NEUPOGEN( )) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing neutropenia-related infections and mobilizing hematopoietic stem cells. ...CONCLUSIONS: This systematic literature review and meta-analysi …
PURPOSE: Filgrastim (NEUPOGEN( )) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventin …
Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.
Kim MG, Han N, Lee EK, Kim T. Kim MG, et al. Bone Marrow Transplant. 2015 Apr;50(4):523-30. doi: 10.1038/bmt.2014.297. Epub 2015 Jan 12. Bone Marrow Transplant. 2015. PMID: 25581410
Results showed similar CD34+ cell collection yields for pegfilgrastim and filgrastim (SDM -0.08, 95% CI: -0.388 to 0.228). On comparison with filgrastim, pegfilgrastim showed a significantly earlier apheresis onset time (SDM: -0.512, 95% CI: -0.973 to -0.050) and re …
Results showed similar CD34+ cell collection yields for pegfilgrastim and filgrastim (SDM -0.08, 95% CI: -0.388 to 0.228). On compari …
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Citron ML, et al. J Clin Oncol. 2003 Apr 15;21(8):1431-9. doi: 10.1200/JCO.2003.09.081. Epub 2003 Feb 13. J Clin Oncol. 2003. PMID: 12668651 Clinical Trial.
PATIENTS AND METHODS: A total of 2,005 female patients were randomly assigned to receive one of the following regimens: (I) sequential A x 4 (doses) --> T x 4 --> C x 4 with doses every 3 weeks, (II) sequential A x 4 --> T x 4 --> C x 4 every 2 weeks with filgrasti …
PATIENTS AND METHODS: A total of 2,005 female patients were randomly assigned to receive one of the following regimens: (I) sequential A x 4 …
Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
Botteri E, Krendyukov A, Curigliano G. Botteri E, et al. Eur J Cancer. 2018 Jan;89:49-55. doi: 10.1016/j.ejca.2017.10.034. Epub 2017 Dec 8. Eur J Cancer. 2018. PMID: 29227817
This meta-analysis aimed to compare the clinical efficacy and safety of approved or proposed G-CSF biosimilars (filgrastim or pegfilgrastim) with reference G-CSF in patients with BC. METHODS: A Medline literature search up to March 2017 identified RCTs comparing biosimilar …
This meta-analysis aimed to compare the clinical efficacy and safety of approved or proposed G-CSF biosimilars (filgrastim or pegfilg …
Biosimilarity Assessment of 2 Filgrastim Therapeutics in Healthy Volunteers.
Khandoozi SR, Shahbazi M, Amini H. Khandoozi SR, et al. Clin Pharmacol Drug Dev. 2021 Apr;10(4):346-352. doi: 10.1002/cpdd.856. Epub 2020 Aug 21. Clin Pharmacol Drug Dev. 2021. PMID: 32820861 Clinical Trial.
This study aimed to compare the pharmacokinetic, pharmacodynamic, and safety profiles of a proposed biosimilar and innovator filgrastim therapeutics in healthy volunteers. In a crossover design, 23 subjects received a single subcutaneous injection of 300- g filgrastim …
This study aimed to compare the pharmacokinetic, pharmacodynamic, and safety profiles of a proposed biosimilar and innovator filgrastim …
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Pinto L, et al. Curr Med Res Opin. 2007 Sep;23(9):2283-95. doi: 10.1185/030079907X219599. Curr Med Res Opin. 2007. PMID: 17697451
RESEARCH DESIGN AND METHODS: We searched PubMed and EMBASE for articles published from January 1, 1990 to August 31, 2006 reporting on randomized controlled trials (RCTs) that compared the efficacy and safety of pegfilgrastim versus filgrastim. We only accepted studies in …
RESEARCH DESIGN AND METHODS: We searched PubMed and EMBASE for articles published from January 1, 1990 to August 31, 2006 reporting on rando …
437 results